Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2009
Business Overview: Alnylam is a biopharmaceutical company developing therapeutics based on RNA interference (RNAi). The company has no approved products and generates revenue primarily through strategic alliances (Roche, Takeda, Novartis, Cubist), government contracts, and licensing. As of June 30, 2009, the company had an accumulated deficit of $282.8 million.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2009 | Six Months Ended June 30, 2008 |
|---|---|---|
| Net Revenues | $49,658 | $46,025 |
| Operating Expenses | $80,050 | $62,813 |
| Loss from Operations | $(30,392) | $(16,788) |
| Net Loss | $(30,591) | $(13,999) |
| Net Loss Per Share (Basic & Diluted) | $(0.74) | $(0.34) |
| Cash and Cash Equivalents (End of Period) | $147,870 | $247,536 |
| Total Cash, Equivalents & Marketable Securities | $473,771 | $512,713 |
| Net Cash Used in Operating Activities | $(34,688) | $86,350 |
| Deferred Revenue (Total) | $312,239 | $330,000 (approx.) |
Note: Total Cash, Equivalents & Marketable Securities calculated as Cash ($147,870) + Current Marketable Securities ($119,368) + Non-Current Marketable Securities ($206,533).
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 8% year-over-year to $49.7 million, driven primarily by the Takeda alliance (revenue increased from $2.1M to $10.8M) and the new Cubist alliance ($1.4M recognized). This was partially offset by a decrease in government contract revenue due to the wind-down of the DTRA program.
- Expense Increase: Operating expenses rose 27% to $80.1 million. Research and Development (R&D) expenses increased 28% to $63.9 million, largely due to an $11.0 million upfront license fee paid to Isis Pharmaceuticals for single-stranded RNAi (ssRNAi) technology and increased clinical trial costs for ALN-VSP and ALN-RSV.
- Liquidity Position: Cash and cash equivalents decreased by $43.9 million during the period. Net cash used in operating activities was $34.7 million, a reversal from the $86.4 million provided in the prior year, primarily due to the net loss and a $17.7 million decrease in deferred revenue.
- Investment Activity: The company made an additional $10.0 million investment in its joint venture, Regulus Therapeutics Inc.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue incurring net losses for the foreseeable future. The company believes its existing cash, cash equivalents, and marketable securities ($473.8 million), combined with expected revenue from alliances, will fund operations for at least the next several years.
- Clinical Progress:
- ALN-RSV01: Phase II trials in lung transplant patients showed safety and tolerability; exploratory data showed a statistically significant decrease in new or progressive bronchiolitis obliterans syndrome.
- ALN-VSP: Phase I study for liver cancer initiated in March 2009.
- ALN-TTR: Announced in August 2009 as the next Investigational New Drug (IND) candidate for TTR amyloidosis.
- Strategic Alliances:
- Novartis: Extended collaboration through October 2010; Novartis purchased additional shares to maintain 13.4% ownership.
- Isis: Amended agreement to focus on ssRNAi; Alnylam paid $11.0 million upfront.
- Cubist: New alliance for RSV treatment; $20.0 million upfront payment received.
- Risks and Contingencies:
- Patent Litigation: In June 2009, Alnylam joined Max Planck in suing Whitehead Institute, MIT, and UMass regarding the prosecution of "Tuschl I" and "Tuschl II" patent applications.
- Regulatory Risk: No RNAi therapeutics have been approved by the FDA; success depends on demonstrating safety and efficacy of a new drug class.
- Capital Needs: While current funds are sufficient for several years, the company may require additional financing for clinical trials and commercialization, which could result in dilution.
Key Facts for Investor Verification
- Burn Rate: Verify the sustainability of the $34.7 million operating cash burn over the six-month period against the $473.8 million cash balance.
- Revenue Recognition: Confirm the straight-line recognition periods for large upfront payments (e.g., Takeda over 7 years, Cubist over 7 years, Roche over 5 years) and the impact of deferred revenue on future earnings.
- Isis Agreement Impact: Assess the long-term value of the ssRNAi technology acquired for $11.0 million against the immediate expense impact on the income statement.
- Patent Portfolio: Monitor the outcome of the litigation against Whitehead/MIT/UMass, as the company's exclusivity in RNAi therapeutics relies heavily on these patents.
- Clinical Milestones: Track the progression of ALN-RSV01 (Phase II) and ALN-VSP (Phase I) as these are the primary drivers for future milestone payments and potential product revenue.